Advance AI and AtScale named OpenAI Select Partners

By Splitfeed EditorialLast updated Oct 20, 2026, 13:11 UTC

On October 20, 2026, two companies received OpenAI Select Partner status on the same day. Advance AI LLC, the company behind MedoraMD, a product aimed at the medical or healthcare space based on its name, was announced as a Select Partner, with the news distributed via PR Newswire and picked up by Morningstar. AtScale, a data and analytics platform, received the same designation hours later, announced through Business Wire. The simultaneous timing of both announcements suggests a coordinated release rather than coincidental alignment.

The OpenAI Select Partner designation signals a formal, tiered relationship between OpenAI and commercial partners, implying closer access to models, support, or go-to-market resources than standard API customers receive. For Advance AI LLC, the designation carries particular weight given that MedoraMD operates in healthcare, a domain where AI integration faces regulatory scrutiny and trust barriers. For AtScale, which sits in the enterprise data layer, the partnership points to ongoing efforts to embed large language model capabilities into business intelligence infrastructure. Both cases reflect how OpenAI is expanding its partner ecosystem across distinct verticals rather than concentrating on a single industry.

No reactions from the Pro-AI, Anti-AI, or Middle Ground camps have been published at this stage. Typically, the Pro-AI camp would welcome such partnerships as evidence of AI moving into consequential, real-world applications where it can demonstrate measurable value. The Anti-AI camp would likely raise concerns about the pace of AI adoption in sensitive sectors like healthcare, questioning whether oversight and safety standards are keeping up. The Middle Ground camp would probably focus on the specifics of what the Select Partner designation actually requires of partners in terms of responsible deployment.

The details worth watching include any public disclosure from Advance AI LLC about how MedoraMD integrates OpenAI models in clinical or administrative workflows, and whether AtScale publishes specifics about which OpenAI capabilities it will offer enterprise customers. Regulatory responses to AI tools in healthcare contexts, particularly from bodies like the FDA, could also shape how meaningful the MedoraMD partnership turns out to be in practice.